Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. (Nasdaq: EMBC) is a leading medical technology company, dedicated to developing innovative technologies, services, and solutions that advance clinical therapies for patients and enhance clinical processes for healthcare providers. The company’s core products include the BD Pyxis, PureWick, and Phasix, which have significantly impacted healthcare delivery and patient outcomes.
Embecta has recently celebrated an important milestone, marking 100 years since the development of the first syringe dedicated to insulin delivery. This heritage underscores its deep-rooted commitment to improving the lives of people with diabetes. Embecta’s global impact is further enhanced through partnerships with leading advocacy and professional groups, striving to raise awareness and provide better solutions for diabetes care.
Financially, Embecta has shown robust performance, consistently demonstrating strong revenue growth. The company's Board of Directors recently declared a quarterly cash dividend of $0.15 per share, payable on September 13, 2023. Embecta regularly evaluates its financial results on both a reported and Constant Currency basis to provide a clear picture of its operational performance, excluding the effects of currency fluctuations.
Embecta continues to spearhead significant projects and initiatives. For instance, its recent symposium at the Advanced Technologies & Treatments for Diabetes (ATTD) international conference showcased the company’s commitment to innovative insulin pump therapies for type 2 diabetes. Furthermore, Embecta has been proactive in responding to regulatory requirements like the EU MDR and GDPR, ensuring compliance while continuously improving its products and services.
With approximately 2,000 dedicated employees worldwide, Embecta leverages its rich legacy and innovative spirit to empower people with diabetes to live their best lives. Through strategic partnerships and a relentless focus on quality and reliability, Embecta remains at the forefront of diabetes care.
Campbell Soup Company (NYSE:CPB) announced the appointment of
Embecta Corp. (Nasdaq: EMBC) recently celebrated the grand opening of its new global headquarters in Parsippany, New Jersey, a significant step for the diabetes care company following its spinoff from Becton, Dickinson and Company in April 2022. The 55,600-square-foot office will house the leadership team, global support functions, and North American commercial operations, supporting approximately 2,000 employees worldwide. CEO Devdatt Kurdikar highlighted the strategic advantages of the location, including access to a skilled workforce and transportation. New Jersey Governor Phil Murphy praised Embecta's commitment to expanding the state's public health infrastructure.
Embecta Corp. (Nasdaq: EMBC), a leading diabetes care company, announced that it will host a conference call on February 14, 2023, at 8:00 a.m. ET to discuss its fiscal Q1 2023 financial results and provide operational updates. Investors can join via a live webcast or teleconference. The call will include a question and answer session, and a replay will be available later that day on the company's investor relations website. As a major player in insulin delivery, Embecta aims to support people with diabetes through innovative solutions, leveraging its nearly century-long legacy.
Embecta Corp. (Nasdaq: EMBC) reported its financial results for the fiscal year ended September 30, 2022. Revenues decreased to $1,129.5 million, down 3.1% year-over-year. The fourth quarter saw revenues of $274.6 million, an 8.7% decline. U.S. and international revenues fell 1.5% and 4.8%, respectively. Gross profit was $774.9 million with a margin of 68.6%. Net income was $223.6 million, a sharp drop from $414.8 million the prior year, influenced by a $58.9 million impairment charge. The company announced a dividend of $0.15 per share and provided preliminary fiscal 2023 guidance of revenues between $1,050 to $1,073 million.
The Board of Directors of Embecta Corp. (NASDAQ: EMBC) has announced a quarterly cash dividend of $0.15 per share, set to be paid on January 11, 2023. This dividend will be distributed to stockholders registered by the close of business on December 30, 2022. Embecta, a leading diabetes care company, leverages nearly a century of experience in insulin delivery to improve the lives of people living with diabetes.
Embecta Corp. (NASDAQ: EMBC) has announced its participation in the upcoming J.P. Morgan Healthcare Conference on January 11, 2023, at 9:45 a.m. PT / 12:45 p.m. ET. The company, known for its significant role in diabetes care, previously operated under Becton, Dickinson and Company. Interested parties can access audio webcasts of the presentation through the Company’s investor relations website. With nearly 100 years in insulin delivery, Embecta aims to enhance the lives of individuals with diabetes through innovative solutions and a dedicated workforce of over 2,000 employees worldwide.
Embecta Corp. (EMBC) and Intuity Medical announced a co-promotional agreement to market the POGO Automatic® Blood Glucose Monitoring System across the U.S., effective immediately. Embecta, a leader in diabetes care following its spin-off from BD, aims to enhance diabetes management solutions with this innovative device. POGO Automatic simplifies blood glucose testing using a 10-test cartridge technology, making it the only FDA-cleared automatic blood glucose monitor. This partnership expands Embecta's offerings while supporting Intuity's mission to improve diabetes care.
Embecta Corp. (Nasdaq: EMBC) announced it will host a conference call on December 20, 2022, at 8:00 a.m. ET to discuss its fiscal Q4 and full-year 2022 financial results, along with preliminary guidance for fiscal year 2023. As a leading diabetes care company, Embecta aims to leverage its nearly 100-year expertise in insulin delivery to enhance life quality for diabetes patients. The call will discuss significant operational updates, and a replay will be available post-call on their investor relations website.
Embecta Corp. (Nasdaq: EMBC) celebrated National Diabetes Awareness Month by ringing the Nasdaq Opening Bell on November 1, 2022. The event involved advocacy and professional groups focused on improving diabetes care. CEO Devdatt Kurdikar emphasized the importance of education and resources for those living with diabetes. The milestone also marks 100 years since the first successful insulin injection, highlighting the estimated 537 million people living with diabetes globally, many unaware of their condition.
Embecta Corp. (Nasdaq: EMBC) announced participation in two investor conferences in September 2022. The company will take part in a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 8 at 8:00 a.m. ET in Boston, MA. Additionally, it will engage in a fireside chat at the 20th Annual Global Healthcare Conference on September 13 at 2:55 p.m. ET in New York, NY. Audio webcasts of these events will be available on the investor relations section of the company's website.
FAQ
What is the current stock price of Embecta (EMBC)?
What is the market cap of Embecta (EMBC)?
What does Embecta Corp. specialize in?
What are some of Embecta's key products?
How long has Embecta been involved in diabetes care?
What recent financial milestone has Embecta achieved?
How does Embecta report its financial results?
What strategic initiatives is Embecta currently focusing on?
How does Embecta contribute to diabetes awareness?
Where are Embecta's main manufacturing operations located?
How does Embecta support its workforce?
What is the significance of Embecta's recent symposium at ATTD?
